Davunetide

发表于由

Davunetide; 纯度: 98.85%

Davunetide 是一种八个氨基酸多肽，来源于活性依赖性神经保护蛋白 (ADNP)，一种存在于哺乳动物中枢神经系统中的神经营养因子。Davunetide 具有神经保护、神经营养和认知保护特性。Davunetide 是一种微管稳定肽 (microtubule-stabilizing)，在体外与神经元特异性βIII微管蛋白相互作用并稳定其活性。Davunetide 可透过血脑屏障，无毒。Davunetide 抑制Aβ聚集和Aβ诱导的神经毒性。

Davunetideamp;;

Davunetide Chemical Structure

CAS No. : 211439-12-2

规格 价格 是否有货 数量
1 mg ￥500 In-stock
5 mg ￥1000 In-stock
10 mg ￥1700 In-stock
25 mg ￥3400 In-stock
50 mg ; 询价 ;
100 mg ; 询价 ;

* Please select Quantity before adding items.

Davunetide 相关产品

bull;相关化合物库:

  • Drug Repurposing Compound Library Plus
  • Clinical Compound Library Plus
  • Bioactive Compound Library Plus
  • Cell Cycle/DNA Damage Compound Library
  • Neuronal Signaling Compound Library
  • Clinical Compound Library
  • Anti-Aging Compound Library
  • Drug Repurposing Compound Library
  • Diabetes Related Compound Library
  • Cytoskeleton Compound Library
  • Anti-Alzheimer’s Disease Compound Library
  • Neuroprotective Compound Library
  • Anti-Lung Cancer Compound Library
  • Neurodegenerative Disease-related Compound Library
  • Rare Diseases Drug Library
  • Peptide Library

生物活性

Davunetide is an eight amino acid snippet derived from activity-dependent neuroprotective protein (ADNP), a neurotrophic factor that exists in the mammalian CNS. Davunetide possesses neuroprotective, neurotrophic and cognitive protective roperties. Davunetide, a microtubule-stabilizing peptide, interacts with and stabilises neuron-specific βIII-tubulin in vitro. Davunetide penetrates the blood-brain barrier and is non-toxic. Davunetide inhibits Aβ aggregation and Aβ-induced neurotoxicity[1][2][3].

体内研究
(In Vivo)

Davunetide (2 μg/kg; Intranasally; daily, 5 days a week, for 16 weeks) shows protective effects for central nervous system complications in a diabetes rat model[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Sprague-Dawley rats (Induced by an i.p. streptozotocin (STZ) injection)[3]
Dosage: 2 μg/kg
Administration: Intranasally beginning on the day following the STZ injection and were given daily, 5 days a week, for 16 weeks
Result: Impaired spatial memory of the diabetic rats was observed in the water maze by attenuated learning curve and worsened performance in the probe memory test. Davunetide treatment significantly improved both measurements.

Clinical Trial

分子量

824.92

Formula

C36H60N10O12
CAS 号

211439-12-2
Sequence Shortening

NAPVSIPQ
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Sealed storage, away from moisture

Powder -80deg;C 2 years
-20deg;C 1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture)
溶解性数据
In Vitro:;

H2O : ≥ 250 mg/mL (303.06 mM)

DMSO : 125 mg/mL (151.53 mM; Need ultrasonic)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.2122 mL 6.0612 mL 12.1224 mL
5 mM 0.2424 mL 1.2122 mL 2.4245 mL
10 mM 0.1212 mL 0.6061 mL 1.2122 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂：;10% DMSO ;; 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (2.52 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (2.52 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
*以上所有助溶剂都可在 MCE 网站选购。
参考文献

  • [1]. Quraishe S, et al. NAP (davunetide) rescues neuronal dysfunction in a Drosophila model of tauopathy. Mol Psychiatry. 2013;18(7):834-842.

    [2]. Zhang J, et al. Davunetide improves spatial learning and memory in Alzheimer’s disease-associated rats. Physiol Behav. 2017;174:67-73.

    [3]. Idan-Feldman A, et al. Davunetide (NAP) as a preventative treatment for central nervous system complications in a diabetes rat model. Neurobiol Dis. 2011;44(3):327-339.